2026 Global: Crispr Technology Market-Competitive Review (2032) report
Description
The 2026 Global: Crispr Technology Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Editas Medicine, headquartered in Cambridge, United States, remains a player in therapeutic CRISPR applications, advancing programs focused on ocular conditions and systemic genetic diseases. The company combines a genome editing platform with clinical execution, aiming to translate laboratory discoveries into patient therapies and to refine delivery and safety. CRISPR Therapeutics, based in Zug, Switzerland, advances CRISPR/Cas9 and newer editing modalities for diverse monogenic and complex diseases, leveraging strategic collaborations with biopharma and clinical trials. Its Swiss registration reflects a transatlantic footprint, coupled with a broad pipeline spanning hematology and metabolic disorders. Intellia Therapeutics, headquartered in Cambridge, United States, pursues both in vivo and ex vivo genome editing, with core investments in delivery technologies and solid partnerships with large pharmaceutical firms. Collectively, these three firms anchor a triad of U.S. and European leadership, driving platform diversification, regulatory engagement, and early-stage pipelines that shape clinical and scientific expectations for the CRISPR market.
Beam Therapeutics, headquartered in Cambridge, United States, pioneers base editing for therapeutic and research applications, aiming to correct point mutations while minimizing double-strand breaks. Its platform complements conventional CRISPR editing by enabling precise, programmable nucleobase changes that expand targetable diseases and delivery strategies. Caribou Biosciences, based in Berkeley, United States, focuses on CRISPR-Cas9 architectures and modular gene editing tools that support research, development, and oncology programs, collaborating with partners to translate concept to clinic. Synthego, located in Redwood City, United States, commercializes CRISPR genome engineering capabilities, supplying automation, synthetic biology, and standardization for researchers and biotech companies, accelerating discovery and scale. Collectively, Beam, Caribou, and Synthego illustrate a shift toward precision editing, scalable service models, and enabling technologies that broaden access to gene editing across discovery, development, and manufacturing ecosystems. These firms complement the early therapeutic ambitions of the market while underpinning infrastructure for research, assay development, and regulatory readiness.
Scribe Therapeutics, headquartered in South San Francisco, United States, advances next-generation CRISPR tooling and delivery modalities, collaborating with biopharma and academic partners to drive clinical translation. Mammoth Biosciences, based in South San Francisco, United States, integrates CRISPR diagnostics and genome editing platforms, aiming to empower rapid assay development and therapeutic exploration with scalable manufacturing options. Inscripta, headquartered in Boulder, United States, leverages high-throughput, multi-mode editing capabilities on a scalable platform, enabling concurrent editing across large libraries for research and drug discovery. eGenesis, anchored in Cambridge, United States, seeks xenotransplantation solutions through CRISPR-enabled genome modification, pursuing organs and tissues with improved compatibility and safety. Collectively, these four firms reflect the maturation of CRISPR as a platform technology across discovery, translational research, and manufacturing, highlighting diversification of tools, delivery challenges, and the evolution of regulatory and clinical pathways. These developments collectively shape investment, policy discourse, and future therapeutic horizons for patient access.
Editas Medicine, headquartered in Cambridge, United States, remains a player in therapeutic CRISPR applications, advancing programs focused on ocular conditions and systemic genetic diseases. The company combines a genome editing platform with clinical execution, aiming to translate laboratory discoveries into patient therapies and to refine delivery and safety. CRISPR Therapeutics, based in Zug, Switzerland, advances CRISPR/Cas9 and newer editing modalities for diverse monogenic and complex diseases, leveraging strategic collaborations with biopharma and clinical trials. Its Swiss registration reflects a transatlantic footprint, coupled with a broad pipeline spanning hematology and metabolic disorders. Intellia Therapeutics, headquartered in Cambridge, United States, pursues both in vivo and ex vivo genome editing, with core investments in delivery technologies and solid partnerships with large pharmaceutical firms. Collectively, these three firms anchor a triad of U.S. and European leadership, driving platform diversification, regulatory engagement, and early-stage pipelines that shape clinical and scientific expectations for the CRISPR market.
Beam Therapeutics, headquartered in Cambridge, United States, pioneers base editing for therapeutic and research applications, aiming to correct point mutations while minimizing double-strand breaks. Its platform complements conventional CRISPR editing by enabling precise, programmable nucleobase changes that expand targetable diseases and delivery strategies. Caribou Biosciences, based in Berkeley, United States, focuses on CRISPR-Cas9 architectures and modular gene editing tools that support research, development, and oncology programs, collaborating with partners to translate concept to clinic. Synthego, located in Redwood City, United States, commercializes CRISPR genome engineering capabilities, supplying automation, synthetic biology, and standardization for researchers and biotech companies, accelerating discovery and scale. Collectively, Beam, Caribou, and Synthego illustrate a shift toward precision editing, scalable service models, and enabling technologies that broaden access to gene editing across discovery, development, and manufacturing ecosystems. These firms complement the early therapeutic ambitions of the market while underpinning infrastructure for research, assay development, and regulatory readiness.
Scribe Therapeutics, headquartered in South San Francisco, United States, advances next-generation CRISPR tooling and delivery modalities, collaborating with biopharma and academic partners to drive clinical translation. Mammoth Biosciences, based in South San Francisco, United States, integrates CRISPR diagnostics and genome editing platforms, aiming to empower rapid assay development and therapeutic exploration with scalable manufacturing options. Inscripta, headquartered in Boulder, United States, leverages high-throughput, multi-mode editing capabilities on a scalable platform, enabling concurrent editing across large libraries for research and drug discovery. eGenesis, anchored in Cambridge, United States, seeks xenotransplantation solutions through CRISPR-enabled genome modification, pursuing organs and tissues with improved compatibility and safety. Collectively, these four firms reflect the maturation of CRISPR as a platform technology across discovery, translational research, and manufacturing, highlighting diversification of tools, delivery challenges, and the evolution of regulatory and clinical pathways. These developments collectively shape investment, policy discourse, and future therapeutic horizons for patient access.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
